Mechanisms of resistance for HNSCC to cisplatin (CDDP), the foundational chemotherapeutic agent in the treatment of this disease, remain poorly understood. We previously demonstrated that cisplatin resistance (CR) can be overcome by targeting Trk receptor. In the current study, we explored the potential mechanistic role of the BDNF-TrkB signaling system in the development of CDDP resistance in HNSCC. Utilizing an in vitro system of acquired CR, we confirmed a substantial up-regulation of both BDNF and TrkB at the protein and mRNA levels in CR cells, suggesting an autocrine pathway dysregulation in this system. Exogenous BDNF stimulation led to an enhanced expression of the drug-resistance and anti-apoptotic proteins MDR1 and XiAP, respectively, in a dose-dependently manner, demonstrating a key role for BDNF-TrkB signaling in modulating the response to cytotoxic agents. In addition, modulation of TrkB expression induced an enhanced sensitivity of cells to CDDP in HNSCC. Moreover, genetic suppression of TrkB resulted in changes in expression of Bim, XiAP, and MDR1 contributing to HNSCC survival. To elucidate intracellular signaling pathways responsible for mechanisms underlying BDNF/TrkB induced CDDP-resistance, we analyzed expression levels of these molecules following inhibition of Akt. Inhibition of Akt eliminated BDNF effect on MDR1 and Bim expression in OSC-19P cells as well as modulated expressions of MDR1, Bim, and XiAP in OSC-19CR cells. These results suggest BDNF/TrkB system plays critical roles in CDDP-resistance development by utilizing Akt-dependent signaling pathways.
References
[1]
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
[2]
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, et al. (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351–360.
[3]
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, et al. (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350: 1937–1944.
[4]
Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, et al. (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14: 2901–2907.
[5]
Coley HM (2009) Mechanisms and consequences of chemotherapy resistance in breast cancer. European Journal of Cancer Supplements 7: 3–7.
[6]
Stewart DJ (2007) Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63: 12–31.
[7]
Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, et al. (2002) Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62: 6462–6466.
[8]
Middlemas DS, Kihl BK, Moody NM (1999) Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents. J Neurooncol 45: 27–36.
[9]
Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, et al. (2010) TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 29: 2047–2059.
[10]
Lai PC, Chiu TH, Huang YT (2010) Overexpression of BDNF and TrkB in human bladder cancer specimens. Oncol Rep 24: 1265–1270.
[11]
Desmet CJ, Peeper DS (2006) The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci 63: 755–759.
[12]
Han L, Zhang Z, Qin W, Sun W (2007) Neurotrophic receptor TrkB: Is it a predictor of poor prognosis for carcinoma patients? Med Hypotheses 68: 407–409.
[13]
Yilmaz T, Jiffar T, de la Garza G, Lin H, Milas Z, et al. (2010) Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol Ther 10:
[14]
Huang YZ, McNamara JO (2010) Mutual regulation of Src family kinases and the neurotrophin receptor TrkB. J Biol Chem 285: 8207–8217.
[15]
Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL (2005) A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood 105: 4429–4436.
[16]
Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, et al. (2011) KISS1 mediates platinum sensitivity and metastasis in head and neck squamous cell carcinoma. Oncogene.
[17]
Kupferman ME, Jayakumar A, Zhou G, Xie T, Dakak-Yazici Y, et al. (2009) Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol 8: 117–127.
[18]
Li Z, Tan F, Thiele CJ (2007) Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells. Mol Cancer Ther 6: 3113–3121.
[19]
Holcik M, Korneluk RG (2001) XIAP, the guardian angel. Nat Rev Mol Cell Biol 2: 550–556.
[20]
O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, et al. (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17: 384–395.
[21]
Almeida S, Laco M, Cunha-Oliveira T, Oliveira CR, Rego AC (2009) BDNF regulates BIM expression levels in 3-nitropropionic acid-treated cortical neurons. Neurobiol Dis 35: 448–456.
[22]
Boisvert-Adamo K, Aplin AE (2008) Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 27: 3301–3312.
[23]
Schmelzle T, Mailleux AA, Overholtzer M, Carroll JS, Solimini NL, et al. (2007) Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci U S A 104: 3787–3792.
[24]
Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, et al. (2004) Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034–1039.
[25]
Geiger TR, Peeper DS (2005) The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res 65: 7033–7036.
[26]
Sengupta S, Mantha AK, Mitra S, Bhakat KK (2011) Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene 30: 482–493.
[27]
Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, et al. (2011) Development of a drug resistance model for hepatoblastoma. Int J Oncol 38: 447–454.
[28]
Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, et al. (2010) MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12: 628–636.
[29]
Nemati F, Daniel C, Arvelo F, Legrier ME, Froget B, et al. (2010) Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts. Anticancer Drugs 21: 25–32.
[30]
Allen KE, Weiss GJ (2010) Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 9: 3126–3136.
[31]
Poplawski T, Tomaszewska K, Galicki M, Morawiec Z, Blasiak J (2008) Promoter methylation of cancer-related genes in gastric carcinoma. Exp Oncol 30: 112–116.
[32]
Yague E, Armesilla AL, Harrison G, Elliott J, Sardini A, et al. (2003) P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 278: 10344–10352.
[33]
Baker EK, Johnstone RW, Zalcberg JR, El-Osta A (2005) Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24: 8061–8075.
[34]
Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW (2010) Histone Methyltransferase MLL1 Regulates MDR1 Transcription and Chemoresistance. Cancer Res 70: 8726–8735.
[35]
Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, et al. (1997) Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 3: 2025–2032.
[36]
Sharma G, Mirza S, Parshad R, Srivastava A, Datta Gupta S, et al. (2010) CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 43: 373–379.
[37]
Schulte JH, Schramm A, Klein-Hitpass L, Klenk M, Wessels H, et al. (2005) Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. Oncogene 24: 165–177.
[38]
Kermani P, Hempstead B (2007) Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med 17: 140–143.
[39]
Li Z, Thiele CJ (2007) Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway. Expert Opin Ther Targets 11: 1611–1621.
[40]
Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S, et al. (2006) Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl 457–465.
[41]
Zhu N, Gu L, Li F, Zhou M (2008) Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther 7: 1101–1109.
[42]
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857–868.
[43]
Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, et al. (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118: 3051–3064.
